Polar Capital's David Pinniger has said there will be a "second stage" of biotech companies coming onto the market, providing the sector with the potential for further robust returns as it approaches the halfway point of a decade-long cycle.
Pinniger, who runs the $427m Polar Capital Biotechnology fund, said people questioned whether biotech had further to run when the fund was launched on 31 October 2013 as the NASDAQ Biotechnology index...
Industry Voice: Chris Taylor discusses the outlook for Japan, explaining why corporates are producing record aggregate profits and profits growth.
Comes in on 9 December 2019
Latest news and analysis
Primarily smart-beta products
Revealed – successes across all 11 categories